A Double Blind , Randomized, Multicenter Study of Second Line Treatment of Endostar rh Recombined Endostatin with Single Docetaxel In NSCLC Patients.
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Endostatin (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Simcere Pharmaceutical Group
- 31 Dec 2008 New trial record.